source
- Tango Therapeutics reports 82% response rate for PRMT5 inhibitor combo in pancreatic cancer trialTango Therapeutics announced a 14% reduction in its workforce while also presenting new data on its PRMT5 inhibitor combined with Revolution Medicines’ RAS(ON) inhibitor Rasonque at the ESMO 2026 m…
- Taysha and Neurogene close in on first Rett syndrome gene therapy as 2027 readouts loomTwo companies, Taysha Gene Therapies and Neurogene, are nearing the final stage of development for gene therapies targeting Rett syndrome, a rare neurodevelopmental disorder with limited treatment…